Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Top Cited Papers
Open Access
- 1 March 2002
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 1 (2), 117-123
- https://doi.org/10.1016/s1535-6108(02)00039-9
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancersSeminars in Oncology, 2001
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- EGFR and cancer prognosisEuropean Journal Of Cancer, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- INTRODUCTIONThe Oncologist, 2000
- Expression, Function and Activation of the Proto-oncogenec-kitProduct in Human Leukemia CellsLeukemia & Lymphoma, 1993
- Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinicJournal of Clinical Immunology, 1991
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cellsNature, 1984